get a key
steadybase-$ company VIR
account_id none on file
legal_name Vir Biotechnology, Inc.
ticker VIR
cik 1706431
domain vir.bio
entry_point_account_id none on file
name Vir Biotechnology Inc.
exchange Nasdaq
sector Health Care
calls 2 filings 1 executives 7 family 0
why_nownone on file
calls
SG&A expenses in the first quarter of 2024 were $36.3 million compared to $46.8 million in the same period in 2023. The decrease was primarily driven by disciplined expense management, which resulted in a significant reduction in external expenses.

May 2, 2024 / receipt, needs a key / Sung Li, CFO | earnings call 2024-05-02 | transcript b924d3e5-4bff-4f91-b851-716dbb44ba66 | chars 15540-15788 | segment 15

And finally, you can expect us to be strong stewards of capital and have a disciplined approach to capital allocation and expense management.

Aug 3, 2023 / receipt, needs a key / Dong Li, CFO | earnings call 2023-08-03 | transcript 8b48470a-e3c3-42a7-be17-57983f781091 | chars 17779-17920 | segment 18

filings
Ending headcount (full-time & part-time) 362 381 (19) (5%)

ir_statement / Sep 16, 2026 / receipt

executives
De Backer Executive Vice President - receipt
Dong Li CFO - receipt
Dr. Marianne DeBacker CEO - receipt
Dr. Phil Pang Chief Medical Officer - receipt
Johanna Friedl-Naderer Executive Vice President and Chief Operating Officer - receipt
Sung Lee Executive Vice President and Chief Financial Officer - receipt
Sung Li CFO - receipt
familynone on file
upcoming
2026-11-04 earnings call scheduled ir
changes
2023-02-16 Chief Financial Officer, departed sec_8k
2023-02-16 Executive Vice President and Chief Financial Officer, appointed sec_8k
2023-01-25 Executive Vice President, appointed sec_8k
2022-04-07 Executive Vice President and Chief Operating Officer, appointed sec_8k
mcp_package_hint
steadybase-$